Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review - Poll - MDSpire

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • By

  • Xin Shen

  • Jiangnan Yang

  • Yang Du

  • Deyuan Fu

  • June 4, 2026

  • 0 min

Share

Original Source(s)

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

  • by Xin Shen, Jiangnan Yang, Yang Du, Deyuan Fu

  • June 4, 2026

Related Content

Successful conversion therapy for presumed granulocyte colony-stimulating factor–producing hepatocellular carcinoma: a case report

Advancing Gastrointestinal Cancer Risk Prediction With Patient-Centered Machine Learning: Machine Learning Modeling Study

Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study